Subtitle
Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016
Subtitle
Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016
Proto therapy Time
February 2021
Executive summary
Based on the SEER database, this study reported that for Medicare beneficiaries with a first-time diagnosis of prostate cancer, the utilization of IMRT, proton therapy, and SBRT increased 23.62%, 0.74% and 1.61% respectively (p <0.0001) while brachytherapy decreased 17.04% (p <0.0001).
IMRT is the primary mode of treatment. Utilization of brachytherapy decreased significantly despite the efficacy and cost-effectiveness. Cost per beneficiary decreased $340.24 annually (p = 0.0065). Age, registry region, and Gleason score were all associated with expenditures.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
March 2024
Longitudinal Assessment of Quality of Life in Nasopharyngeal Cancer Patients Treated with Intensity-Modulated Proton Therapy and Volumetric Modulated Arc Therapy at Different Time Points.
Proton Therapy Publication
October 2023
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Proton Therapy Publication
November 2023
Postmastectomy Intensity Modulated Proton Therapy: 5-Year Oncologic and Patient-Reported Outcomes.
Webinar
May 8, 2023
Proton Therapy: DynamicARC vs IMPT Treatment Plans & Case Studies
Craig
Stevens
Xuanfeng (Leo)
Ding
Matthew
Hall
Frederic
Genin
Rohan L.
Deraniyagala
Proton Therapy Publication
August 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
October 2022
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
Proton Therapy Publication
November 2022
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.